Roche, a provider of pharmaceuticals and diagnostics products, is set to acquire Spark Therapeutics, a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, for $4.3bn. “Spark Therapeutics’ proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases. In particular, Spark Therapeutics’ hemophilia A program could become a new therapeutic option for people living with this disease. We are also excited to continue the investments in Spark Therapeutics’ broad product portfolio and commitment to Philadelphia as a center of excellence,” Severin Schwan, Roche CEO. 22/12/2019: CMA clears Roche's $4.3bn takeover of Spark Therapeutics.